Clinical trial
Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors
NCT02746081 · Bayer, Industry · Completed
Key facts
| NCT number | NCT02746081 |
|---|---|
| Title | Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors |
| Official title | An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-tumor Activity in Patients With… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | BAY1436032 |
| Enrollment | 81 |
| Start date | May 26, 2016 |
| Primary completion | Nov 8, 2018 |
| Completion | Dec 3, 2024 |
| First posted | Apr 21, 2016 |
| Last update posted | Dec 18, 2024 |
| Countries | Denmark, Germany, Japan, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: